Please assess the completion status of the following clinical trial:

Trial Title: Induction Chemotherapy Followed By Cetuximab and Radiation in HPV-Associated Resectable Stage III/IV Oropharynx Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed squamous cell carcinoma of the oropharynx as determined by Hematoxylin and eosin (H\&E) staining~  * Newly diagnosed disease~ * Resectable disease OR disease that is expected to become resectable after study treatment~ * Stage III, IVA, or IVB disease as determined by imaging studies (computed tomography (CT) scan with IV contrast or magnetic resonance imaging (MRI) required) and a complete head and neck exam~* Paraffin-embedded tumor specimen available for central confirmation of HPV-associated disease as determined by H\&E staining and in-situ hybridization (ISH) for HPV-16 and immunohistochemistry (IHC) for p16~  * HPV-associated disease is defined as p16 IHC-positive and/or HPV-16 ISH-positive~ * Non-HPV-associated disease is defined as p16 IHC-negative~ * NOTE: If there is limited tumor material, p16 IHC will be performed before HPV-16 ISH~* Measurable disease of the primary tumor or nodes by clinical and radiographic methods, defined as a lesion that is ≥ 2 cm in at least one dimension by clinical exam AND by radiographic exam with CT scan or MRI (or a lesion that is ≥ 1 cm in at least one dimension if the radiographic exam utilizes spiral CT scan)~* No primary tumor or nodal metastasis fixed to the carotid artery, skull base, or cervical spine~* No evidence of distant metastases~* Eastern Cooperative Oncology Group performance status 0-1~* Granulocytes ≥ 1,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total serum bilirubin ≤ 1.5 mg/dL~* Creatinine clearance ≥ 60 mL/min~* Negative pregnancy test~* Fertile patients must use effective contraception~* No history of another malignancy (except for carcinoma in situ of the cervix and/or nonmelanomatous skin cancer) unless it has been curatively treated and the patient has been disease-free for ≥ 2 years~* Patients with any of the following within the past 6 months are eligible provided they have been evaluated by a cardiologist and/or neurologist before study entry:~  * New York Heart Association (NYHA) class III-IV congestive heart failure~ * Cerebrovascular accident or transient ischemic attack~ * Unstable angina~ * Myocardial infarction (with or without ST elevation)~Exclusion Criteria:~* Prior chemotherapy~* Prior radiotherapy above the clavicles~* Prior surgery with curative intent for this disease (complete head and neck exam with biopsy allowed)~* Prior therapy specifically and directly targeting the EGFR pathway~* Prior severe infusion reaction to a monoclonal antibody~* Uncontrolled diabetes, uncontrolled infection despite antibiotics, or uncontrolled hypertension within the past 30 days~* Concurrent illness likely to interfere with study therapy or to prevent surgical resection~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): After induction therapy with Paclitaxel and Cisplatin, patients undergo low-dose intensity-modulated radiotherapy (IMRT) 5 days per week for approximately 5 weeks (27 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 6 weeks.
- Group 2 (Type: EXPERIMENTAL): After induction therapy with Paclitaxel and Cisplatin, patients undergo standard-dose IMRT 5 days per week for approximately 6 weeks (33 fractions). Patients also receive cetuximab IV over 1-2 hours once weekly for 7 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).